Pacific Biosciences (PACB) officer receives large option and RSU awards

Rhea-AI Filing Summary

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported that company officer Mark Van Oene acquired new equity awards. He received a stock option for 1,000,000 shares at an exercise price of $0.00 per share and a grant of 500,000 shares of common stock.

The 500,000 shares are in the form of Restricted Stock Units that vest in three equal annual installments on February 15, 2027, 2028, and 2029, contingent on continued service. The 1,000,000-share option vests in 36 equal monthly installments beginning on March 27, 2026, also subject to his continued status as a service provider.

Insider Trade Summary

Net Buyer: 500,000 shares

Net Buy 2 txns

Insider Van Oene Mark

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	1,000,000	$0.00	$0.00
Grant/Award	Common Stock	500,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 1,000,000 shares (Direct); Common Stock — 2,242,638 shares (Direct)

Footnotes (2)

1. F1. Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on February 15 of each of 2027, 2028, and 2029, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates.
2. F2. The shares subject to the option will vest in 36 equal monthly installments beginning on March 27, 2026, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/03/2026 - 06:13 PM Learn about SEC filing dates

FAQ

What equity awards did PACB officer Mark Van Oene receive?

Mark Van Oene received a stock option for 1,000,000 shares and 500,000 shares of common stock as Restricted Stock Units. Both awards were granted at $0.00 per share as compensation, contingent on his continued service with PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

How do Mark Van Oene’s 500,000 PACB RSUs vest?

The 500,000 PACB Restricted Stock Units vest in three equal annual installments on February 15 of 2027, 2028, and 2029. Each installment depends on Mark Van Oene maintaining his status as a service provider through the relevant vesting date.

What is the vesting schedule for Mark Van Oene’s 1,000,000 PACB stock options?

The 1,000,000 PACB stock options vest in 36 equal monthly installments starting March 27, 2026. Each monthly tranche becomes exercisable only if Mark Van Oene continues in service through the applicable vesting dates specified in the grant.

Were Mark Van Oene’s PACB equity awards open-market purchases?

No, the transactions were coded as grants or awards, not open-market purchases. Both the 1,000,000 stock options and 500,000 RSUs were acquired at $0.00 per share as part of compensation, rather than being bought on the market.

How many PACB common shares does Mark Van Oene hold after the grant?

After the grant, Mark Van Oene holds 2,242,638 shares of PACB common stock directly. This total reflects the addition of 500,000 granted shares and is reported as his ownership following the non-derivative transaction on February 27, 2026.

Are Mark Van Oene’s PACB equity awards subject to continued service?

Yes, both awards require continued service. The RSUs vest annually through 2029 only if he remains a service provider, and the option’s 36 monthly vesting installments beginning March 27, 2026 have the same continued-service condition.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Van Oene Mark

(Last) (First) (Middle)

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.,

1305 O'BRIEN DRIVE

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. [ PACB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/27/2026		A		500,000(1)	A	$0	2,242,638	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.68	02/27/2026		A		1,000,000		(2)	02/27/2036	Common Stock	1,000,000	$0	1,000,000	D

Explanation of Responses:

1. Each share is represented by a Restricted Stock Unit ("RSU"). The RSUs will vest in equal annual installments on February 15 of each of 2027, 2028, and 2029, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates.

2. The shares subject to the option will vest in 36 equal monthly installments beginning on March 27, 2026, subject to the Reporting Person's continued status as a service provider through the applicable vesting dates.

Remarks:

Chief Operating Officer

	/s/ Michele Farmer, Attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.